Search research articles
Contact Us
Filters
Showing results (11-20 of 1,155) with videos related to
Page
of 116
Sort By:
Blood
|
January 9, 2016
Obinutuzumab: the more the merrier?
Jan A Burger
Blood
|
April 12, 2012
BRAF mutation: supporting diversity in HCL
Jan A Burger
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2011
Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer
R A Burger
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 8, 2019
Going through Changes: Surface IgM Levels during CLL Therapy with Ibrutinib
Jan A Burger
Expert Opinion on Medical Diagnostics
|
March 14, 2013
The times they are a-changin': prognostic markers in the new era of BCR-targeting therapies for CLL
Jan A Burger
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2007
Experience with bevacizumab in the management of epithelial ovarian cancer
Robert A Burger
Current Hematologic Malignancy Reports
|
November 23, 2011
Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia
Jan A Burger
Advances in Experimental Medicine and Biology
|
September 10, 2013
The CLL cell microenvironment
Jan A Burger
Current Opinion in Oncology
|
September 11, 2012
Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape
Jan A Burger
Cancer Journal (Sudbury, Mass.)
|
August 16, 2021
Integrating New Therapies for Chronic Lymphocytic Leukemia
Jan A Burger
Page
of 116
Search research articles
Search
Showing results (11-20 of 1,155) with videos related to
Sort By:
Page
of 116
Blood
|
January 9, 2016
Obinutuzumab: the more the merrier?
Jan A Burger
Blood
|
April 12, 2012
BRAF mutation: supporting diversity in HCL
Jan A Burger
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2011
Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer
R A Burger
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 8, 2019
Going through Changes: Surface IgM Levels during CLL Therapy with Ibrutinib
Jan A Burger
Expert Opinion on Medical Diagnostics
|
March 14, 2013
The times they are a-changin': prognostic markers in the new era of BCR-targeting therapies for CLL
Jan A Burger
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 10, 2007
Experience with bevacizumab in the management of epithelial ovarian cancer
Robert A Burger
Current Hematologic Malignancy Reports
|
November 23, 2011
Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia
Jan A Burger
Advances in Experimental Medicine and Biology
|
September 10, 2013
The CLL cell microenvironment
Jan A Burger
Current Opinion in Oncology
|
September 11, 2012
Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape
Jan A Burger
Cancer Journal (Sudbury, Mass.)
|
August 16, 2021
Integrating New Therapies for Chronic Lymphocytic Leukemia
Jan A Burger
Page
of 116